PI3K inhibitors have previously shown activity in melanoma, regardless of BRAF mutation status (32, 48), in response to PI3K family members being highly expressed in metastatic melanoma, and PTEN being frequently deleted (49). This evidence concerns the gene BRAF and metastatic melanoma.